Stock HLUN B H. LUNDBECK A/S
Add to a list

ETFs H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 11:20:01 13/03/2026 GMT 		5-day change 1st Jan Change
37.43 DKK -0.13% Intraday chart for H. Lundbeck A/S -0.95% -13.30%
03-10 H. Lundbeck A/S Appoints Markus Kede as Senior Vice President and Chief AI Officer and Joins Executive Leadership Team, Effective July 1, 2026 CI
03-10 H. Lundbeck Names Chief Artificial Intelligence Officer MT

ETFs positioned on H. Lundbeck A/S

Name Varia. Jan 1. Weight AuM
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD ETF First Trust IPOX Europe Equity Opportunities ETF - Distributing - USD
-1.71%0.25% 4 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF ETF Vanguard International Equity Index Funds - Vanguard FTSE All-World ex-US ETF
-3.02%0% 33,076 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF Acc - EUR
+0.80%0% 864 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF - Distributing - EUR
+0.79%0% 64 M€
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Acc - EUR
+0.61%0% 661 M€
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Distributing - EUR
+0.18%0% 87 M€
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD ETF CI Marret Alternative Absolute Return Bond ETF - CAD
0.00%-0% 16 M€

Company Profile

Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,039
Sector
Pharmaceuticals
Calendar
03-19 - Ex-dividend date - 1.15 DKK
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.48DKK
Average target price
46.12DKK
Spread / Average Target
+23.07%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. ETFs H. Lundbeck A/S
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener -
United-States
MarketScreener Canada -
Canada

MIDDLE EAST

MarketScreener Saudi Arabia -
Saudi Arabia
MarketScreener UAE Emirates -
United Arab Emirates

EUROPE

Zonebourse -
France
MarketScreener Deutschland -
Deutschland
Zonebourse Suisse -
Suisse
MarketScreener Schweiz -
Schweiz
MarketScreener Italia -
Italia
MarketScreener Österreich -
Österreich
MarketScreener België -
België
MarketScreener Nederland -
Nederland
MarketScreener España -
España
MarketScreener Sverige -
Sverige
MarketScreener UK -
United Kingdom

APAC

MarketScreener Australia -
Australia
MarketScreener India -
India
MarketScreener Hong Kong -
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition